Efficacy of a Mindfulness-Based Intervention in Patients With Cardiovascular Implantable Electronic Device
Launched by CHIEN CHIH-YIN · Aug 31, 2023
Trial Information
Current as of July 01, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
This study with randomized clinical trial design (randomized clinical trial) and qualitative research, which is a qualitative mixed-methods research. Patients were randomly assigned to the experimental group and the control group in a 1:1 manner. The experimental group received the mindfulness-based intervention designed and routine care , and the control group received general routine care. Both groups completed a total of four questionnaires at the pretest (T0), discharge (T1), the first month of discharge (T2), and the third month of discharge (T3), including anxiety, depression, resilie...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Patients receiving implanted cardiac devices for the first time (including cardiac defibrillator ICD and Pacemaker).
- • 2. Adults over 20 years old.
- • 3. Those who have clear consciousness and can communicate in Chinese and Taiwanese.
- • 4. Score of 8 or above on the Hospital Anxiety or Depression Scale.
- • 5. Barthel Index above 70 points.
- Exclusion Criteria:
- • 1. Diagnosed with dementia by a physician.
- • 2. Diagnosed with mental disorders, including cognitive disorders, organic psychosis and affective psychosis.
- • 3. Patients who have been diagnosed with cancer.
- • 4. Long-term bed ridden.
About Chien Chih Yin
Chien Chih-Yin is a clinical trial sponsor dedicated to advancing medical research and innovation through rigorous scientific investigation. With a focus on developing novel therapeutic solutions, the organization is committed to conducting high-quality clinical trials that adhere to ethical standards and regulatory guidelines. Chien Chih-Yin collaborates with leading researchers and healthcare professionals to ensure the integrity of its studies, aiming to improve patient outcomes and contribute to the broader medical community. Through its strategic approach, the sponsor seeks to bridge the gap between laboratory discoveries and clinical applications, ultimately enhancing the quality of healthcare worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Taipei, , Taiwan
Patients applied
Trial Officials
CY Chien, PI
Study Chair
MKC/MMH
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported